Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450803 | 0.85 | TDP1 (0.52) | TDP1TSHRMAPK1VCAM1PDE7A | |
| SCHEMBL30490230 | 0.82 | TDP1 (0.57) | TDP1TSHRMAPK1VCAM1PDE7A | |
| SCHEMBL8013048 | 0.82 | TDP1 (0.57) | TDP1TSHRMAPK1VCAM1PDE7A | |
| SCHEMBL288026 | 0.80 | TDP1 (0.48) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL29705523 | 0.80 | TDP1 (0.48) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL10727741 | 0.80 | TDP1 (0.67) | TDP1TSHRMAPK1VCAM1PDE7A | |
| SCHEMBL29435969 | 0.80 | TDP1 (0.67) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL4603872 | 0.80 | TDP1 (0.67) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL18663666 | 0.78 | TDP1 (0.53) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL899707 | 0.77 | TDP1 (0.52) | TDP1TSHRMAPK1VCAM1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| CN-101410120-A | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES INC (US) | 2009-04-15 | — | — | CN | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | TDP1 3075/4885TSHR 4758/4885MAPK1 1327/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | TDP1 3075/4885TSHR 4758/4885MAPK1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.